Cartalax (20mg)

$72.00

1 Unit
$72 per unit
$72.00
2 Units
$70.2 per unit (save 3% per unit)
$140.40
$144.00
3 Units
$68.4 per unit (save 5% per unit)
$205.20
$216.00
4 Units
$66.6 per unit (save 8% per unit)
$266.40
$288.00
5 Units
$64.8 per unit (save 10% per unit)
$324.00
$360.00
6 Units
$63 per unit (save 13% per unit)
$378.00
$432.00
7 Units
$61.2 per unit (save 15% per unit)
$428.40
$504.00
8 Units
$59.4 per unit (save 18% per unit)
$475.20
$576.00
9 Units
$57.6 per unit (save 20% per unit)
$518.40
$648.00
10 Units
$55.8 per unit (save 23% per unit)
$558.00
$720.00
Category:

Description

Cartalax peptide is a synthetic tripeptide (Ala-Glu-Asp) developed as a cartilage-specific bioregulator to support joint and tissue health.  It functions at the cellular and genetic level to promote cartilage regeneration and protect against degeneration.

Cartilage Repair & Regeneration: Cartalax stimulates chondrocytes (cartilage cells) to increase production of collagen and proteoglycans, essential structural components that maintain cartilage elasticity and cushioning.
Anti-Inflammatory Effects: It reduces inflammation by inhibiting matrix metalloproteinases (MMP-9) and pro-inflammatory cytokines, helping to prevent cartilage breakdown.
Anti-Aging & Cellular Protection: Cartalax modulates aging markers such as p53, p16, and p21, while boosting SIRT-6, a longevity-associated protein, to slow cellular senescence and enhance tissue resilience.
Stress Resilience & Growth Signaling: It enhances IGF-1 levels and may support TERT and NF-κB pathways, promoting cell repair, growth, and stress adaptation.
Joint Mobility & Recovery: By improving cartilage quality and reducing stiffness, Cartalax supports joint function, making it beneficial for osteoarthritis management, post-injury recovery, and athletic performance.
Systemic Tissue Support: Beyond joints, Cartalax shows potential in improving skin fibroblast activity, nephroprotection, and bone metabolism via effects on thyroid C cells.
While primarily studied in Russia and Eastern Europe, Cartalax is considered experimental in most Western countries and is not FDA-approved. It is typically used in short 10–20 day cycles via oral capsules or injectables, with a favorable safety profile in short-term use.

Related products